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Although a correlation between polymorphisms of NOD-like receptor family-pyrin domain 
containing 3 (NLRP3) and predisposition to type 1 diabetes (T1D) has been identified, 
the potential function and activation of the NLRP3 inflammasome in T1D have not been 
clarified. The present study shows that non-obese diabetic mice exhibited increased 
NLRP3, and pro-IL-1β gene expression in pancreatic lymph nodes (PLNs). Similar 
increases in gene expression of NLRP3, apoptosis associated speck like protein (ASC) 
and pro-IL-1β were induced by multiple low doses of streptozotocin (STZ) in C57BL/6 
mice. In addition, diabetic C57BL/6 mice also exhibited increased IL-1β protein expres-
sion in the pancreatic tissue at day 7, which remained elevated until day 15. Diabetic 
mice also showed increased positive caspase-1 macrophages in the PLNs, which were 
decreased in NLRP3−/− mice, but not in ASC−/− mice, after STZ treatment. NLRP3- and 
IL-1R-deficient mice, but not ASC-deficient mice, showed reduced incidence of diabe-
tes, less insulitis, lower hyperglycemia, and normal insulin levels compared to wild-type 
(WT) diabetic mice. Notably, these mice also displayed a decrease in IL-17-producing 
CD4 and CD8 T cells (Th17 and Tc17) and IFN-γ-producing CD4 and CD8 T cells (Th1 
and Tc1) in the PLNs. Following STZ treatment to induce T1D, NLRP3-deficient mice 
also exhibited an increase in myeloid-derived suppressor cell and mast cell numbers 
in the PLNs along with a significant increase in IL-6, IL-10, and IL-4 expression in the 
pancreatic tissue. Interestingly, diabetic mice revealed increased circulating expres-
sion of genes related to mitochondrial DNA, such as cytochrome b and cytochrome 
c, but not NADH dehydrogenase subunit 6 (NADH). Mitochondrial DNA (mDNA) from 
diabetic mice, but not from non-diabetic mice, induced significant IL-1β production 
and caspase-1 activation by WT macrophages, which was reduced in NLRP3−/− mac-
rophages. Finally, mDNA administration in  vivo increased Th17/Tc17/Th1/Tc1 cells in 
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inTrODUcTiOn
Type 1 diabetes (T1D) results from the autoimmune destruc-
tion of insulin-producing pancreatic β cells (1) in genetically 
predisposed individuals. It is currently known that both innate 
and adaptive immune responses play a role in the pathogenesis of 
the disease. Adaptive immunity has been studied thoroughly over 
the past few years with several therapies, such as anti-CD3 mono-
clonal antibody therapy (2), anti-CD20 (3), and antithymocyte 
globulin treatment, reaching clinical trials (4). However, whether 
the innate immune response triggers T1D remains poorly under-
stood and controversial. In non-obese diabetic (NOD) mice, a 
deficiency of toll-like receptor (TLR) 2 (5) or the MyD88 adaptor 
molecule (6) correlated with protection from developing T1D, 
yet TLR2−/− (7) and MyD88−/− (8) mice are susceptible to T1D 
induced by multiple low doses of streptozotocin (MLD-STZ).
Although many studies in the literature on innate immunity 
focused on the TLRs in T1D, the contribution of nucleotide bind-
ing and oligomerization domains (NOD), such as nucleotide-
binding domain-like receptor (NLR), in the development of 
T1D needs to be explored. The NOD-like receptor family-pyrin 
domain containing 3 (NLRP3) is a member of the NLR family. 
NLRP3 assembles a complex called the inflammasome through 
oligomerization with apoptosis-associated speck-like protein 
(ASC) in myeloid cells, such as dendritic cells (9) and mac-
rophages (10). This process leads to the autocatalytic activation 
of caspase-1 (11), which in turn cleaves pro-IL-1β and pro-IL-18 
into mature forms (12). The NLRP3 inflammasome is thought to 
play an important role as a defense mechanism against pathogens 
and damage signals called danger-associated molecular patterns 
(DAMPs), such as uric acid crystals, ATP, high-mobility group 
box 1, and the heat-shock proteins hsp70 and hsp90 (13).
Other activators, such as pore-forming toxins (14) and UV 
radiation, also activate the NLRP3 inflammasome by reducing 
intracellular K+ concentrations or by promoting cytosolic release 
of lysosomal cathepsins (13). Certain activators, such as ATP, are 
able to induce mitochondrial dysfunction and apoptosis, which 
results in the release of oxidized mitochondrial DNA (mDNA) into 
the cytosol then binds and activates the NLRP3 inflammasome 
(12). The role of the NLRP3 inflammasome in autoinflammatory 
diseases, such as type 2 diabetes (T2D) (15), and autoimmune 
diseases, such as experimental autoimmune encephalomyelitis 
(EAE) (16), has been recognized. In this context, inhibition of 
caspase-1 suppresses IL-17 production by CD4 T cells and γδ  
T cells and the induction of EAE, which suggests that IL-1β 
induces the Th17 responses in autoimmunity (17). In fact, IL-1β 
synergizes with IL-6 and IL-23 to trigger the expression of the 
IRF4 and RORγt transcription factors as well as driving the 
induction of Th17 cells (18).
Despite this evidence, little is known about the role of the 
NLRP3 inflammasome in T1D. Interestingly, an association 
study in Brazil identified two single-nucleotide polymorphisms 
in NLRP3 that are associated with T1D (19). A recent study has 
also demonstrated that NLRP3 deficiency plays a protective role 
against T1D by inhibiting chemokines and chemokine receptors 
involved in immune cell migration to pancreatic islets (20). 
However, the activator of the NLRP3 receptor in T1D and the 
precise immunological mechanisms related to T1D pathogen-
esis remain elusive. Our data demonstrate that mDNA isolated 
from diabetic mice displays an intrinsic capacity to activate the 
NLRP3 inflammasome in macrophages. Furthermore, increased 
expression of mDNA-related genes was detected in diabetic mice 
sera. Finally, mDNA administration causes IL-1β production 
associated with the induction of pathogenic Th17/Tc17/Th1/Tc1 
responses in the pancreatic lymph nodes (PLNs), which results in 
STZ-induced T1D onset.
resUlTs
Diabetic Mice have Upregulation of 
nlrP3 inflammasome gene expression 
and il-1β Production in Plns and 
Pancreas
To investigate the role of the NLRP3 inflammasome in the 
pathogenesis of T1D, C57BL/6 wild-type (WT) male mice were 
inoculated intraperitoneally with MLD-STZ (40 mg/kg) for five 
consecutive days and were assessed for mRNA expression of 
NLRP3, ASC and pro-IL-β in the PLNs at 7 and 15 days after start-
ing the STZ injections. Increased gene expression of the NLRP3, 
ASC, and pro-IL-1β genes was found in the PLNs of diabetic mice 
at 7 and 15 days after STZ treatment compared to non-diabetic 
mice treated with the vehicle (Figures 1A–C). We also observed 
a peak of protein IL-1β levels at day 7 after STZ-induced T1D, 
which decreased at day 15, but remained significantly elevated 
compared to non-diabetic mice (Figure  1D). In addition, we 
detected a significant increase of NLRP3 protein expression on 
day 7 using a Western blot, which remained increased at day 15 
after STZ-induced T1D (Figure 1E). In agreement, we noted an 
increase of caspase-1-positive macrophage percentage at day 7, 
which slightly decreased at day 15 in the PLNs after STZ-induced 
T1D (Figure 1F). Notably, we observed a significant decline in 
the caspase-1-positive macrophage percentage in the PLNs of 
NLRP3-deficient mice, but not in ASC-deficient mice, not only 
the PLNs and precipitated T1D onset, which was abolished in NLRP3−/− mice. Overall, 
our results demonstrate that mDNA-mediated NLRP3 activation triggers caspase-1- 
dependent IL-1β production and contributes to pathogenic cellular responses during the 
development of STZ-induced T1D.
Keywords: nlrP3 inflammasome, type 1 diabetes, cytokines, il-17-producing cD4 T cells (Th17), il-17-producing 
cD8 T cells (Tc17), iFnγ-producing cD4 T cells (Th1), iFnγ-producing cD8 T cells (Tc1)
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FigUre 1 | nOD-like receptor family-pyrin domain containing 3 (nlrP3) inflammasome-related protein and gene expression profile during type 1 
diabetes. Relative gene expression of NLRP3 (a), apoptosis-associated speck-like protein (ASC) (B), and pro-IL-1β (c) by RT-PCR in the pancreatic lymph nodes 
(PLNs) of streptozotocin (STZ)-induced diabetic or non-diabetic mice (vehicle). The time course of IL-1β production was determined in the pancreatic tissue by an 
ELISA assay (D). The kinetics of NLRP3 expression was quantified 7 or 15 days after STZ by Western blotting (e). The PLNs were removed, and caspase-1 
activation was measured with a fluorescent cell-permeable probe that binds to activated caspase-1 (FLICA), after 7 and 15 days of STZ or vehicle administration 
(F,g). The concentrations of IL-1β (h) and IL-18 (i) were determined in the pancreatic tissue by an ELISA assay. The relative gene expression of NLRP3 (J) and 
pro-IL-1β (K) was assessed by RT-PCR in the PLNs of prediabetic (8 weeks of age) and non-obese diabetic (NOD) mice (20 weeks of age). The results are 
expressed as the mean ± SEM (n = 9 in the vehicle-injected wild-type (WT) group; n = 15 in the STZ-administered WT group; n = 15 in the STZ-administered 
ASC−/− group; n = 15 in the STZ-administered NLRP3−/− group; n = 18 in the prediabetic group and n = 12 in the diabetic NOD group). *p ≤ 0.05 compared to the 
vehicle-injected WT group or prediabetic group, #p ≤ 0.05 compared to the STZ-administered WT group. Significant differences between two groups were 
compared by Student’s t-test or three or more groups by one-way ANOVA followed by Tukey’s multiple-comparison test. The results are representative of a single 
experiment repeated three times.
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on day 7 but also on day 15 compared to WT mice after STZ treat-
ment (Figures 1F,G). Similarly, the IL-1β protein levels decreased 
significantly in the pancreatic tissue of NLRP3-deficient mice, 
but not in ASC-deficient mice after STZ treatment (Figure 1H). 
Conversely, the IL-18 protein levels were reduced significantly 
only in the pancreatic tissue of ASC-deficient mice compared to 
4Carlos et al. NLRP3 Inflammasome in T1D
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WT mice after STZ treatment (Figure 1I). Additionally, geneti-
cally determined NOD mice displayed increased gene expression 
of NLRP3 and pro-IL-1β in the PLNs compared to prediabetic 
mice (Figures 1J,K). These findings demonstrated that NLRP3-
dependent IL-1β expression and caspase-1 activation is induced 
in macrophages in PLNs during T1D.
il-1r signaling confers susceptibility to 
the Development of sTZ-induced T1D
Diabetic WT mice exhibited body weight loss compared to non-
diabetic mice (Figures 2A,E). On the other hand, whereas cas-
pase-1/11−/− mice maintained the body weight loss (Figure 2A), 
IL-1R−/− mice had a very minor body weight loss after STZ 
treatment (Figure 2E). Similarly, 66% of caspase-1/11−/− mice in 
comparison to 50% of IL-1R−/− mice developed T1D at day 15 
after STZ treatment (Figures 2B,F). Additionally, blood glucose 
levels were significantly lower in IL-1R−/− mice (Figure 2G), but 
were not affected in the caspase-1/11−/− mice compared to WT 
mice (Figure  2C). Serum insulin levels increased in IL-1R−/− 
(Figure  2H), but not in caspase-1/11−/− mice (Figure  2D) 
compared to WT mice after 15  days of the STZ treatment, 
although the increase in IL-1R−/− animals was not significant. 
The pancreatic islets from non-diabetic WT mice appeared to be 
structurally normal with no leukocytic infiltration (Figure 2I). 
However, pancreatic islets of diabetic WT mice revealed invasive 
insulitis (Figure 2J), whereas a less extensive inflammatory infil-
tration was observed in the IL-1R−/− mice after STZ (Figure 2K). 
Moreover, immunostaining showed the islets of non-diabetic 
mice had a high number of β cells containing insulin (Figure 2L). 
The islets of diabetic WT mice had fewer β cells (Figure  2M), 
while those cells from the IL-1R−/− mice had many more β cells 
positive for insulin (Figure 2N). Collectively, these results suggest 
that IL-1R signaling contributes to pancreatic islet inflammation, 
which leads to insulin-producing β cell damage and development 
of T1D.
il-1r signaling increases Pathogenic Th1/
Th17/Tc17 Populations during sTZ-
induced T1D
Despite the fact that there was no observable difference in the 
percentage of CD4+IL-17+ cells (Figure S1A in Supplementary 
Material), the absolute number of this population was significantly 
reduced in the PLNs of IL-1R−/− compared to diabetic WT mice 
after STZ treatment (Figure S1D in Supplementary Material). In 
addition, the percentage of CD8+IL-17+ cells did not differ among 
the several experimental groups (Figure S1B in Supplementary 
Material), but there was a significant decrease in the absolute num-
ber of this cell population in the PLNs of IL-1R−/− mice compared 
to diabetic WT mice (Figure S1E in Supplementary Material). 
The frequency and absolute numbers of CD4+IFN-γ+ cells in the 
PLNs were significantly reduced in IL-1R−/− mice compared to 
diabetic WT mice (Figures S1C,F in Supplementary Material). 
There was a significant increase in the protein IL-6 levels in the 
pancreatic tissue of IL-1R−/− mice compared to the diabetic WT 
mice (Figure S1G in Supplementary Material). Despite the lack of 
differences in expression levels, IL-17 decreased in IL-1R−/− mice 
compared to diabetic WT mice after STZ treatment (Figure S1H 
in Supplementary Material). Despite a trend toward increase, no 
differences in the IFN-γ or TNF-α expression between the experi-
mental groups were observed (Figures S1I,J in Supplementary 
Material). In contrast, the IL-4 and IL-10 levels were significantly 
increased in the pancreatic tissues of IL-1R−/− mice compared 
to diabetic WT mice after STZ treatment (Figures S1K,L in 
Supplementary Material). These data support the idea that the 
IL-1R signaling pathway plays an important role in driving the 
Th17/Tc17/Th1 immune response after STZ induces T1D.
nlrP3 activation is required for insulitis 
and Development of sTZ-induced T1D
To further explore whether NLRP3 and ASC are involved in 
T1D onset, we used the MLD-STZ model in WT, NLRP3−/−, and 
ASC−/− mice, and disease incidence was monitored. STZ-treated 
diabetic WT and ASC−/− mice had a cumulative disease incidence 
of 100%, while the NLRP3−/− mice developed resistance and had a 
reduction of disease incidence of 40% (Figure 3A). As expected, 
WT, NLRP3−/−, and ASC−/− mice did not become hyperglycemic 
and had normal serum insulin levels after vehicle administration 
(Figures  3B–D). The WT and ASC−/− mice became hypergly-
cemic at day 15 after STZ treatment, whereas NLRP3−/− had 
a significant decrease of glycemia levels after STZ treatment 
(Figures  3E,F). Importantly, NLRP3−/− presented higher levels 
of insulin in the serum, whereas STZ-injected ASC−/− mice 
maintained unaltered insulin levels compared to WT after STZ 
administration (Figure  3G). Corroborating this observation, 
these mice displayed increased insulin immunohistochemistry 
staining in the pancreatic islets, whereas ASC−/− mice had similar 
staining to WT mice after STZ treatment (Figures 3H,I).
In STZ-administrated mice, we found the appearance of 
more invasive insulitis and reduction of insulin-positive β cells 
(Figures  3J,L,O). Later, we investigate whether the protection 
observed in NLRP3−/− mice against STZ-induced T1D could 
be attributed to a reduced pro-inflammatory response into the 
pancreatic islets. In fact, histological analysis showed that STZ-
injected NLRP3−/− mice had milder inflammatory infiltration 
with less severe insulitis in the pancreatic islets and an increase of 
insulin-positive β cells (Figures 3J,M,P). Non-diabetic WT mice 
did not have moderate or severe insulitis and showed intense 
insulin-positive β cells in the pancreatic islets (Figures 3J,K,N). 
Taken together, our data indicate that an NLRP3-dependent 
mechanism is required for pancreatic islet inflammation, which 
results in insulin-producing β cell damage and T1D development.
nlrP3 activation increases Th17/Tc17 
and Decreases the Myeloid-Derived 
suppressor cell (MDsc) Populations 
during sTZ-induced T1D
The percentage and absolute numbers of CD4+ T cells and CD8+ 
T cells were unaltered in the PLNs of diabetic WT mice compared 
to vehicle-treated mice (Figures 4A–D). However, the percentage 
of CD4+ T cells, but not CD8+ T cells, were significantly reduced 
in the PLNs of NLRP3−/− mice compared to diabetic WT mice 
(Figures  4A,C). In addition, the CD4+IL-17+ cell frequency 
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FigUre 2 | continued 
il-1r deficiency, but not caspase-1/11, confers resistance to type 1 diabetes development. Body weight variation (a,e), cumulative disease incidence 
(B,F), and blood glucose levels (c,g) were detected in caspase-1/11−/−, IL-1R−/−, or wild-type (WT) mice. These clinical parameters were monitored 1, 4, 7, 11, 15, 
and 18 days after the initial streptozotocin (STZ) treatment. The non-diabetic mice only received the sodium citrate (vehicle). The serum insulin concentrations were 
determined at day 15 after the initiation of STZ or vehicle administration (D,h). Pancreatic tissues from vehicle-injected WT (i,l), STZ-treated WT (J,M), and 
STZ-treated IL-1R−/− mice (K,n) were stained with hematoxylin-eosin (H&E) (upper panels) or immunostained for insulin (lower panels), respectively (original 
magnification 400×). The results are expressed as the mean ± SEM (n = 12 in the vehicle-injected WT group; n = 18 in the STZ-administered WT group; n = 18 in 
the STZ-administered caspase-1/11−/− group; and n = 18 in the STZ-administered IL-1R−/− group). #p ≤ 0.05 compared to the STZ-administered WT group. 
Significant differences between the two groups were compared by Student’s t-test or three groups by one-way ANOVA followed by Tukey’s multiple-comparison 
test. The results are representative of a single experiment repeated three times. n.s., not significant.
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and absolute numbers in the PLNs from NLRP3−/−mice 
were significantly decreased compared to diabetic WT mice 
(Figures 4E,F,M). Similarly, the frequency and absolute numbers 
of CD8+IL-17+ cells were significantly reduced in the PLNs of 
these mice (Figures  4G,H). Despite a trend toward reduction, 
there was no significant difference between the percentage and 
absolute numbers of CD4+IFN-γ+ and CD8+IFN-γ+ cells in the 
PLNs of NLRP3−/−mice and diabetic WT mice (Figures 4I–L). 
In parallel, NLRP3 deficiency significantly increased IL-6 and 
IL-4 levels (Figures 5A,D) without alterations in the IL-17 and 
IFN-γ levels (Figures  5B,C) in the pancreatic tissue after STZ 
treatment. Surprisingly, ASC-deficient mice had significantly 
decreased IL-17, IFN-γ, and IL-4 (Figures 5F–H), but the IL-6 
levels remained unaltered (Figure  5E). Our next step was to 
identify whether the resistance observed in NLRP3−/− mice could 
be attributed to the induction of tolerogenic cells in the myeloid 
or lymphoid compartment. Importantly, NLRP3−/− mice had a 
normalization of frequency and absolute numbers of MDSCs in 
the PLNs compared to diabetic WT mice (Figures 5I–K). On the 
other hand, the arginase-1 and iNOS gene expressions decreased 
in the pancreatic tissue of NLRP3−/− mice compared to diabetic 
WT mice (Figures 5L,M), while Foxp3 and TGF-β gene expres-
sion was not altered (Figures 5N,O). Overall, our results showed 
that NLRP3 activation promotes IL-1β production, which in turn 
triggers Th17/Tc17 induction and dampens MDSC expansion in 
STZ-induced T1D.
Mitochondrial Dna Triggers caspase-1-
Dependent il-1β Production by 
Macrophages
Later, we determined the effect of mDNA from non-diabetic mice 
(cmDNA) or from diabetic mice (dmDNA) on NLRP3 inflamma-
some activation. To examine whether the inflammasome is acti-
vated by mDNA, bone marrow-derived macrophages (BMDMs) 
were exposed to different concentrations of mDNA after priming 
with LPS to allow expression of pro-IL-1β. Consistently, IL-1β 
production was significantly increased in BMDMs from WT 
mice after stimulation with dmDNA (10 µg/mL) when compared 
with cells stimulated only with LPS. However, this response was 
reduced in BMDMs from NLRP3−/− mice. On the other hand, 
cmDNA stimulation (5 or 10  µg/mL) after LPS priming did 
not induce IL-1β production (Figure 6A). Conversely, cmDNA 
or dmDNA stimulation (5 or 10 µg/mL) did not change IL-1α 
production in BMDMs from WT mice when compared to LPS-
stimulated cells. Nevertheless, BMDMs from NLRP3−/− mice 
already presented a significant IL-1α reduction when compared 
to BMDMs from WT mice, independent of the stimulus that was 
used (Figure 6B).
Because active caspase-1 is crucial for the cleavage of pro-IL-
1β to its mature and biologically active form, we determined if 
dmDNA is able to trigger the activation of caspase-1. The activa-
tion of caspase-1 was demonstrated by using the FAMYVAD-FMK 
fluorescent inhibitor (FLICA), which binds covalently to active 
caspase-1. Notably, the dmDNA stimulation at a concentration 
of 10  µg/mL induced a significant increase in the percentage 
of caspase-1-positive BMDMs compared BMDMs incubated 
only with LPS, and this effect was inhibited in the BMDMs of 
NLRP3−/− mice. However, cmDNA stimulation at a concentra-
tion of 5 or 10  µg/mL did not promote a significant increase 
in caspase-1-positive BMDMs compared to the LPS stimulus 
alone (Figures 6C,D). Because nigericin is a potent activator of 
the NLRP3 inflammasome, we used this compound as a posi-
tive control in the Western blot assays. Of fact, we detected an 
increase of active IL-1β (p17) expression in the supernatant of 
BMDMs from WT mice exposed to nigericin after LPS priming, 
which was inhibited in BMDMs from NLRP3−/− mice. Similarly, 
the immunoblot analysis showed that the active form of IL-1β 
was being produced in response to dmDNA at a concentration of 
10 µg/mL in the supernatant of the BMDMs from WT mice, but 
this effect was inhibited in BMDMs from NLRP3−/− mice, after 
priming the cells with LPS. Of interesting manner, the expression 
of active form of IL-1β was similar by BMDMs from WT mice 
or NLRP3−/− mice in response to cmDNA at the same concen-
tration (Figures  6E,F). These results suggest that the NLRP3 
inflammasome senses mitochondrial DNA from diabetic mice in 
macrophages and causes caspase-1-dependent IL-1β production.
Mitochondrial Dna from Diabetic Mice 
Precipitates sTZ-induced T1D Onset
The administration of five doses of STZ (40 mg/kg) induces T1D 
as described before. However, the administration of only four 
doses does not have this effect (Figures 7A–D). This result sug-
gests that four doses of STZ do not induce T1D because the doses 
are not sufficient to produce robust β-cell damage. Therefore, we 
tested whether four sub-diabetogenic doses of STZ would cause 
T1D if they were administered with mDNA from diabetic mice 
(three doses each at 5 µg i.p.) to C57BL/6 mice on day 1 before 
and days 6 and 9 after STZ administration. Our findings showed 
that dmDNA administration predisposes animals to T1D onset, 
which was confirmed by 83% disease incidence (Figure 7B) and 
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FigUre 3 | continued 
nOD-like receptor family-pyrin domain containing 3 (nlrP3) deficiency promotes protection against type 1 diabetes development. Cumulative disease 
incidence was monitored in NLRP3−/−, ASC−/−, or wild-type (WT) mice after streptozotocin (STZ) administration (a). The time course of glycemia was monitored or 
blood glucose levels was determined at day 15 after the initiation of vehicle (B,c) or STZ administration (e,F) by a glucometer system Accu-Chek Active. The serum 
insulin concentrations were determined at day 15 after the initiation of STZ or vehicle administration (D,g). The quantitative analysis of insulin-staining pancreatic 
islets (h,i) or semiquantitative scale insulitis score (J). Pancreatic tissues from vehicle-injected WT (K,n), STZ-treated WT (l,O), and STZ-treated NLRP3−/− mice 
(M,P) were stained with hematoxylin-eosin (H&E) (upper panels) or immunostained for insulin (lower panels), respectively (original magnification 400×). The results 
are expressed as the mean ± SEM (n = 12 in the vehicle-injected WT group; n = 24 in the STZ-administered WT group; n = 12 in the vehicle-injected ASC−/− group; 
n = 24 in the STZ-administered ASC−/− group; n = 12 in the vehicle-injected NLRP3−/− group; and n = 24 in the STZ-administered NLRP3−/− group). #p ≤ 0.05 
compared to the STZ-administered WT group. Significant differences between two groups were compared by Student’s t-test or three or more groups by one-way 
ANOVA followed by Tukey’s multiple-comparison test. The results are representative of a single experiment repeated three times or a compilation of two different 
experiments (A). 
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increased blood glucose levels after four sub-diabetogenic doses 
of STZ (Figures  7C,D). Nevertheless, dmDNA administration 
did not affect body weight loss compared with mice only given 
four doses of STZ (Figure 7A). The dmDNA effects in the disease 
incidence and hyperglycemia were abrogated in NLRP3−/− mice, 
since we observed a significant reduction of glycemic levels in 
these mice compared to diabetic WT mice after four doses of STZ 
(Figures 7B–D). As shown in Figure 7E, the group treated only 
with STZ had a striking proportion of insulitis-free islets (96%) 
and some infiltrated areas with peri-insulitis (4%). However, 
more infiltrated areas with peri-insulitis (16%), moderate insulitis 
(34%), and severe insulitis (18%) were observed in mice treated 
with four sub-diabetogenic doses of STZ and dmDNA. On the 
other hand, the pancreatic islets of NLRP3−/− mice revealed more 
insulitis-free islets (74%) and no moderate or severe insulitis 
after the same treatments. Similarly, serum insulin levels further 
decreased in WT mice, but were normalized in NLRP3−/− mice 
treated with dmDNA after STZ (Figure  7F). Thus, these data 
indicate that NLRP3 activation mediated by mDNA from diabetic 
mice is required for the pancreatic islet inflammation involved in 
insulin-producing β cell damage and T1D development.
Mitochondrial Dna induces Pathogenic 
lymphocyte response and Dampens 
Mast cell and MDsc expansion in sTZ-
induced T1D
Considering dmDNA promotes IL-1β production mediated by 
NLRP3 and the established role of IL-1β in Th17 differentiation 
(21, 22), we examined whether NLRP3 is involved in Th17 and 
Tc17 induction in mice treated with mDNA after sub-diabetogenic 
doses of STZ. The dmDNA administration plus STZ was able to 
promote a significant increase of CD4+IL-17+ and CD8+IL-17+ 
absolute numbers in the PLNs of WT mice (Figures  7K,L). 
Importantly, the frequency and absolute numbers of CD4+IL-17+ 
cells were significantly reduced in the PLNs of NLRP3−/− mice 
compared to diabetic WT mice treated with STZ and dmDNA 
(Figures  7G,K,O). Although there were no differences in the 
frequency, the absolute number of CD8+IL-17+ cells was sig-
nificantly decreased in the PLNs of NLRP3−/− mice compared 
to diabetic WT mice after the same treatments (Figures 7H,L). 
Another important observation is the increased frequency and 
absolute numbers of CD4+IFN-γ+ and CD8+IFN-γ+ cells in the 
PLNs of mice treated with mDNA after sub-diabetogenic doses 
of STZ (Figures 7I,J,M,N). Of note, the frequency and absolute 
numbers of CD4+IFN-γ+ cells were significantly decreased in the 
PLNs of NLRP3−/− mice compared to diabetic WT mice treated 
with STZ and dmDNA (Figures  7I,M,P). However, only the 
absolute numbers of CD8+IFN-γ+ cells, but not the percentage, 
were significantly decreased in the PLNs of NLRP3−/− mice com-
pared to diabetic WT mice (Figures 7J,N).
Analysis of circulating mDNA genes, such as NADH 
dehydrogenase subunit 6 (NADH), cytochrome b (Cyt B), and 
cytochrome c (Cyt C), demonstrated a significant increase in 
gene expression of Cyt B and Cyt C, but not NADH, 15 days after 
STZ in diabetic mice compared to vehicle-treated mice (Figures 
S2A–C in Supplementary Material). Interestingly, we observed 
that NLRP3−/− mice treated with STZ and dmDNA exhibited a 
significant increase in the percentage and absolute numbers of 
mast cells (Figures S2D,G in Supplementary Material), but not 
M2 macrophages (Figures 2E,H in Supplementary Material), 
compared to WT and NLRP3−/− mice after only STZ doses. In 
addition, NLRP3−/− mice had a trend to increase the percentage 
and absolute number of monocytic MDSCs compared to WT mice 
treated with STZ and dmDNA (Figures S2F,I in Supplementary 
Material). A coadministration of STZ and dmDNA also signifi-
cantly increased IL-1β levels in the pancreatic tissue of WT mice, 
but significantly decreased IL-1β levels in NLRP3-deficient mice 
(Figure S2J in Supplementary Material). Conversely, the NLRP3 
deficiency caused a significant increase in IL-6 levels (Figure 
S2K in Supplementary Material) without affecting the IL-17, 
IL-23, IFN-γ, and IL-10 levels (Figures S2L–O in Supplementary 
Material) in the pancreatic tissue after dmDNA and STZ adminis-
tration. Taken together, our results showed that NLRP3 activation 
depended on mDNA from diabetic mice for the induction of 
Th17/Tc17/Th1/Tc1 responses and the suppression of mast cells 
and MDSCs in STZ-induced T1D.
DiscUssiOn
Type 1 diabetes is one of the most prevalent autoimmune diseases 
in the world. It affects approximately 10–20 million people and 
develops most frequently in childhood but also can develop in 
adulthood. Similar to other autoimmune disorders, the etiol-
ogy of diabetes remains unclear, but it is known that the risk 
of developing the disease is determined by genetic and envi-
ronmental factors, including viral infections, food, vaccination, 
toxins, and stress (23, 24). A strong association between NLRP3 
M
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polymorphisms and a greater predisposition to the disease has 
been reported in diabetic patients (19).
The NLRP3 inflammasome is a molecular platform required 
for the proteolytic cleavage of caspase-1 and is activated by 
endogenous and exogenous stimuli, including uric acid crystals 
and silica, bacterial toxins, β-amyloid particles, and ATP (12–14). 
After activation, NLRP3 oligomerization and interaction with 
the adapter molecule ASC resulted in activation of caspase-1 and 
expression of active forms of IL-1β and IL-18. Our results showed 
a correlation between increased NLRP3, ASC, and pro-IL-1β 
gene expression in the PLNs, as well as IL-1β, but not IL-18 pro-
tein expression at day 7 in the pancreatic tissue of STZ-induced 
diabetic mice. In addition, pancreatic IL-1β expression remained 
elevated at day 15 through a mechanism dependent on NLRP3 
inflammasome activation. IL-18 expression, after 15  days of 
STZ-induced T1D, was not dependent on NLRP3 inflamma-
some activation. In parallel, we observed an elevated percentage 
of caspase-1-expressing macrophages in the PLNs of diabetic 
mice, which was reduced in mice lacking NLRP3. In addition, 
deficiency of IL-1R and NLRP3 in mice triggered resistance to 
T1D development. This protection observed in IL-1R−/− mice 
was associated with smaller IL-17 production in the pancreatic 
tissue during T1D. NLRP3 deficiency in NOD mice also pro-
tected against T1D through inhibition of chemokines CCL5 and 
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FigUre 7 | continued 
nOD-like receptor family-pyrin domain containing 3 (nlrP3) activation by mitochondrial Dna (mDna) from diabetic mice contributes to Th17/Tc17/
Th1/Tc1 response and leads to type 1 diabetes onset. Body weight variation (a), cumulative disease incidence (B), and time course of glycemia was 
monitored, or blood glucose levels were determined after 15 days of streptozotocin (STZ) (c,D) in wild-type (WT) mice treated only with four doses of STZ (light gray 
bars) plus mDNA from diabetic mice (dmDNA) (black bars) or NLRP3−/− mice treated only with four doses of STZ (dark gray bars) plus dmDNA (white bars). These 
clinical parameters were monitored 1, 7, 10, and 15 days after the initial STZ treatment. The insulitis score was evaluated using a semiquantitative scale (e). The 
serum insulin concentrations were determined at day 15 after the initiation of STZ (F). The percentage and absolute numbers of CD4+IL-17+ (g,K), CD8+IL-17+ 
(h,l), CD4+IFN-γ+ (i,M), and CD8+IFN-γ+ (J,n) cells in the pancreatic lymph nodes (PLNs) was determined by flow cytometry. Representative dot plots of the Th17 
(CD4+IL-17+) and Th1 (CD4+IFN-γ+) percentages in the PLNs, respectively (O,P). Intracellular cytokine levels were detected after stimulation with PMA plus 
ionomycin. The gate was set on CD3-positive lymphocytes. The results are expressed as the mean ± SEM (n = 12 in the WT group administered only with STZ; 
n = 18 in the WT group administered with STZ plus mDNA; n = 12 in the NLRP3−/− group administered only with STZ; and n = 18 NLRP3−/− group administered 
with STZ plus mDNA). *p ≤ 0.05 compared to the WT group treated only with STZ, #p ≤ 0.05 compared to the WT group treated with STZ plus mDNA. Significant 
differences between the groups were compared by one-way ANOVA followed by Tukey’s multiple-comparison test. The results are representative of a single 
experiment repeated three times.
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CXCL10 in the pancreatic islets (20). Taken together, these results 
indicate that NLRP3-dependent IL-1β production accounts for 
T1D onset in the STZ-induced experimental model.
NLRP3 receptor activation plays a crucial role in the induction 
of inflammatory responses and in the subsequent polarization of 
the adaptive immune response. In terms of cellular immunity, 
T CD4 lymphocytes are related to Th1, Th2, Treg, Th9, Th22, and 
Th17 according to their profile of cytokine expression and tran-
scription factors (25). The differentiation of these cell subtypes 
is induced by a differential pattern of anti- or pro-inflammatory 
cytokines produced by macrophages and dendritic cells (26). It 
has been reported that IL-18 and IL-1β play an important role in 
driving Th1 and Th17 cellular responses, respectively (27). Initial 
studies supported a crucial role for IFN-γ-secreting Th1 cells in 
T1D pathogenesis (28, 29). However, this notion was altered by 
the discovery that genetic absence neither IFN-γ nor its receptor 
protect against T1D in NOD mice (30, 31). Notably, Emamaullee 
et al. provided strong evidence about the pathogenic role of Th17 
in T1D by treating animals with either a neutralizing anti-IL-17 
antibody or recombinant IL-25 (32). The deficiency of IL-1R, 
as well as NLRP3 in mice protected against T1D development 
and was associated with reduced Th17/Tc17/Th1 populations in 
the PLNs. Previous studies have also reported that deficiency 
of IL-1R or NLRP3 results in a lower production of IL-17 and 
causes resistance to EAE (16, 33). Similarly, another study 
reported that IL-1Ra-deficient mice spontaneously develop 
arthritis due to the high expression of IL-17 caused by increased 
signaling of IL-1 (34).
Mechanisms involving IL-1β-induced Th17 differentiation 
have been reported. TGF-β induces ROR-γt expression in naïve 
T cells and triggers IL-23R and IL-1R expression, which makes 
these cells receptive to IL-23 and IL-1β (35). In vitro studies have 
shown that IL-1β induces the expression of IRF-4, which posi-
tively regulates IL-21-mediated STAT-3 and ROR-γt transcription 
factor expression (18, 36). Additionally, a role for IL-1β on Th17 
phenotype induction has been attributed to alternative splicing of 
Foxp3 (37). However, there are no reports about the direct effect 
of IL-1β on the induction or expansion of Th1 lymphocytes. 
More recently, the ability of Th17 and Tc17 lymphocytes to be 
converted into Th1 lymphocytes in the presence of IL-12 in T1D 
was also observed (38, 39), demonstrating the considerable plas-
ticity of these cellular subtypes. Therefore, it is possible that the 
reduction in the Th1 lymphocyte population in NLRP3−/− mice 
is due to a defect in the differentiation of Th17/Tc17 lymphocytes 
and their subsequent conversion into Th1 lymphocytes. Taken 
together, our results demonstrate that NLRP3-dependent IL-1β 
expression appears to drive Th17/Tc17/Th1 differentiation under 
inflammatory conditions, such as T1D.
NLRP3 deficiency increased IL-6 and IL-4 protein expression 
in the pancreatic tissue after STZ administration. A study has 
shown that the activation of basophils and mast cells induces 
the secretion of IL-4 and delays the onset of T1D in NOD mice 
(40). Additionally, coculturing mast cells with MDSC leads to 
IL-6, IL-13, and TNF-α production, increasing their suppres-
sor activity (41). MDSCs are increased in the blood of patients 
and experimental models of T1D, but these cells have a defect 
in their suppressor activity (42). Supporting these findings, we 
also observed a positive correlation between increased numbers 
of mast cells and MDSCs in the PLNs of NLRP3−/− mice after 
STZ administration, which indicates a synergistic effect between 
these two cell subtypes in protection against T1D. More recently, 
IL-6 has been involved in the generation of both mouse and 
human MDSC cells (43, 44). Accordingly, we demonstrated 
that mast cells play a regulatory role through IL-6-dependent 
mechanisms during T1D (45). Based on this evidence, we sug-
gest that the increased MDSC population in NLRP3−/− mice 
is due to elevated IL-6 expression, which in turn inhibits the 
inflammatory response in the pancreatic islets and prevents the 
onset of T1D.
Danger-associated molecular patterns are usually found in 
different compartments within cells and are often modified by 
proteolytic and oxidative processes associated with cellular injury 
mechanisms (46). Most DAMPs are released or secreted and exert 
their biological activity through the activation of TLR and NLR 
receptors (47). In particular, mitochondrial DAMPs, including 
mDNA and formylated peptides, stimulate neutrophils via TLR9 
and FPR-1, respectively, after being released into the extracel-
lular space (48). In humans, the presence of mDNA is detected 
in the synovial fluid of patients with arthritis, and intra-articular 
injection of mDNA induces arthritis mediated by the recruitment 
of macrophages and monocytes. Researchers concluded that oxi-
datively damaged DNA bases are major contributors to arthritis 
development (49). Another study also revealed that neutrophil 
mitochondria guide oxidized mDNA in the steady state into 
lysosomes for degradation. On the other hand, blood neutrophils 
from patients with systemic lupus erythematosus (SLE) patients 
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have mitochondrial retention of oxidized nucleoids, indicating 
that a defect in degradation of neutrophil oxidized mDNA might 
contribute to SLE pathogenesis (50).
It is known that excessive oxidative damage to DNA 
impairs the normal repair mechanisms and induces apoptosis 
(51, 52).
Considering that alterations in DNA induced by oxidative 
stress contribute to diabetes progression (53), we addressed 
the in vitro and in vivo effects of mDNA released in response 
to pancreatic damage in T1D in the activation of NLRP3 
inflammasome in macrophages. Macrophages primed with 
LPS and stimulated with mDNA from diabetic mice exhib-
ited increased IL-1β production, caspase-1 expression and 
cleavage of pro-IL-1β in active IL-1β in  vitro. In addition, 
coadministration of mDNA plus four doses of STZ-induced 
pancreatic islet inflammation and led to T1D, which was 
abrogated in NLRP3-deficient mice. mDNA plasma levels 
are significantly elevated in diabetic patients compared with 
healthy controls (54). Likewise, we also detected increased 
expression of mDNA-related genes in the serum of diabetic 
mice. It is plausible that tissue necrosis resulting from beta-
cell death leads to extracellular mDNA release. However, 
it is still puzzling the fact that only mDNA from diabetic 
mice activates the NLRP3 inflammasome. We speculate that 
beta-cell death and DAMP release, such as mDNA, occur 
during the initial phase of diabetes (prediabetic phase). In 
addition, oxidative stress that contributes to beta-cell death 
may induce mDNA oxidation, which turns into an immuno-
genic molecule. In this context, it has been reported that ATP 
induces mitochondrial dysfunction, apoptosis, and oxidized 
mDNA release into the cytosol, which activates the NLRP3 
inflammasome (12). Thus, it seems likely that the presence of 
extracellular mDNA exacerbates inflammation by stimulat-
ing IL-1β production via NLRP3 activation, thereby causing 
massive β-cell destruction and accelerating T1D onset in this 
experimental model.
In summary, we conclude that NLRP3 inflammasome acti-
vation mediated by mitochondrial DNA from diabetic mice 
promotes caspase-1 activation and IL-1β production by mac-
rophages, which drives pathogenic Th17/Tc17/Th1 responses 
and negatively modulates the tolerogenic responses mediated by 
MDSC and mast cells in the PLNs, and leads to the development 
of T1D. Thus, alternative therapies using nucleases or drugs that 
cause extracellular mDNA degradation should be explored in 
human T1D.
aniMals anD MeThODs
animals
This research project was approved by the Animal Research 
Ethics Committee of the Ribeirao Preto Medical School, 
University of São Paulo (no. 001/2008). Male NLRP3−/−, 
IL-1R−/−, and ASC−/− mice generated on the C57BL/6 back-
ground (8–12  weeks old) were obtained from the Isogenic 
Breeding Unit at Ribeirao Preto Medical School, University 
of São Paulo, Ribeirao Preto, Brazil. Female NOD/LtJ mice 
(8–20 weeks old) were obtained from the Jackson Laboratory 
and housed in the animal facility of the Department of 
Biochemistry and Immunology, Ribeirao Preto Medical 
School, at 23–25°C with free access to water and food.
induction of Diabetes by MlD-sTZ
The mice were given daily intraperitoneal injections of 40 mg/kg 
of streptozotocin (Sigma-Aldrich,) dissolved in 0.1 M sodium cit-
rate (pH 4.5) for five consecutive days. Blood glucose levels, body 
weight, and diabetes incidence were monitored weekly. Mice were 
defined as diabetic when glucose levels were ≥230 mg/dL after 
two consecutive determinations under non-fasting conditions.
Flow cytometry analysis of intracellular 
and extracellular Markers
Flow cytometry analysis was performed on samples with 
1 × 106 cells/tube in 100 µL of PBS. First, cell suspensions were 
incubated with 5% normal rabbit serum for 30  min to block 
non-specific binding. Next, antibodies against CD3, CD4, CD8, 
CD25, CD117, FcϵRI, CD11b, Ly6C, CD206, TLR2, and their 
control isotypes (BD Pharmingen, San Diego, CA, USA) were 
added and incubated for 30 min in the dark. IL-17 and IFN-γ 
production was evaluated after in vitro reactivation with PMA 
(25 ng/mL) and ionomycin (1 mg/mL, Sigma-Aldrich) together 
with 10  mg/mL monensin (Sigma-Aldrich) as previously 
described (55). The cells were analyzed using a FACS Canto 
flow cytometer, and the data were analyzed using FlowJo (Tree 
Star) software.
Detection of cytokine levels in Pancreatic 
Tissue
Pancreatic fragments (tail portions) were removed, weighed, and 
placed in a tube containing 700 µL of Complete Protease Inhibitor 
Cocktail (Roche Diagnostics, Abbott Park, IL, USA). The tissue 
was homogenized using a Polytron homogenizer (Thermo Fisher 
Scientific, Waltham, MA, USA) and IL-1∝, IL-1β, IL-18, IL-6, 
IL-17, IL-23, TNF-α, IFN-γ, IL-10, and IL-4 levels were detected 
by ELISA using colorimetric kits according to the manufacturer’s 
instructions (R&D Systems). The results were expressed as the 
mean nanograms ± SEM per gram/tissue (pancreatic tissue) or 
picograms per milliliter (culture supernatant).
Quantification of serum insulin levels
Serum samples were collected 15 days after MLD-STZ adminis-
tration of non-fasting mice. The insulin concentration was deter-
mined using the Mouse Ultrasensitive Insulin ELISA kit (Alpco 
Diagnostics) according to the manufacturer’s instructions.
histological and immunohistochemistry 
analysis
Pancreatic fragments (head portion) were removed, fixed 
in 10% buffered formalin, and embedded in paraffin. Then, 
4–5  µm sections were stained with hematoxylin and eosin 
(Merck, Whitehouse Station, NJ, USA). Immunohistochemistry 
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reactions were performed as previously described (55). The 
degree of insulitis was evaluated using a semiquantitative scale: 
0, intact islet; 1, peri-insulitis; 2, moderate insulitis (<50% of 
the islets infiltrated); and 3, severe insulitis (>50% of the islets 
infiltrated).
culture of BMDMs
The BMDMs from WT and NLRP3−/− mice were differenti-
ated as previously described (56). Briefly, total bone marrow 
cells were cultured for 7  days in RPMI 1640 medium (Sigma-
Aldrich) supplemented with 10% fetal bovine serum (FBS) 
(Life Technologies, Molecular Probes, Carlsbad, CA, USA) and 
30% L-929 cell-conditioned media at 37°C and 5% CO2. The 
cells (0.5 ×  106/well) were stimulated with nigericin (20  µM) 
for 30  min (Sigma-Aldrich), and then mitochondrial DNA 
from non-diabetic or control mice (cmDNA) or diabetic mice 
(dmDNA) at the concentration of 5 or 10 µg/mL for 2 h. Prior 
to stimulation, BMDMs were prestimulated for 4  h with LPS 
(0.5 µg/mL) (InvivoGen).
Western Blotting
Fifty micrograms of extracted proteins were loaded directly 
into sodium dodecyl sulfate (SDS) sample buffer for 10% SDS-
polyacrylamide gel electrophoresis. After transferring the samples 
onto a nitrocellulose membrane (Trans-Blot Transfer Medium; 
Bio-Rad, Hercules, CA, USA), the membranes were blocked 
with 5% milk in Tris buffer solution containing 0.1% Tween 20 
for 1 h and then incubated with antibodies against IL-1β (Santa 
Cruz) or NLRP3 (R&D Systems) overnight at 4°C. Next, the cells 
were incubated with an IgG HRP-conjugated secondary Ab (Cell 
Signaling) for 1  h at room temperature. After the membranes 
were rinsed, the immunocomplexes were developed using an 
enhanced peroxidase/luminol chemiluminescence reaction (ECL 
Western blotting detection reagents; Pierce Biotechnology) and 
exposed to X-ray film with autoradiography (Carestream Health). 
The bands were quantified densitometrically using ImageTool 2.0 
software (University of Texas), and the results were expressed as 
arbitrary units.
active caspase-1 staining
Active caspase-1 was detected using the caspase-1 fluoro-
chrome inhibitor of caspases (FLICA) kit (Immunochemistry 
Technologies) according to the manufacturer’s instructions. 
Briefly, macrophages or PLN cells were adjusted to a volume 
of 0.5 × 106/tube or 1-2 × 106/tube, respectively. Later, the cells 
were stained for F4/80 and FLICA for 30 min at 37°C. The cells 
were then washed two times with PBS containing 10% FBS and 
analyzed directly with flow cytometry on a FACS Canto flow 
cytometer.
Mitochondrial Dna isolation
Pancreata from diabetic and non-diabetic mice (control) 
were used in protocols for isolating the mitochondria. Briefly, 
the pancreatic tissue was cut in pieces and added to 50 mL of 
medium (Hepes 10 mM, saccharose 250 mM e EGTA 1 mM) at 
pH 7.2 and homogenized for 15 s. Later, the pancreatic tissue was 
centrifuged at 600 g for 5 min, and the supernatant was collected 
and centrifuged at 2,000 g for 10 min. The pellet containing the 
isolated mitochondria was recovered. The mitochondria were 
sonicated at an amplitude of 100% (10 sonicagens of 30 s with 
30  s intervals). Then, the suspension of lysed mitochondria 
was centrifuged at 12,000  g for 10  min at 4°C followed by 
centrifugation at 100,000 g at 4°C for 30 min. The supernatant 
from this centrifugation was used for DNA extraction with the 
phenol–chloroform–isoamyl alcohol mixture (Sigma-Aldrich). 
Finally, DNA quantitation was determined with a Nanodrop 
2000 (Thermo Technologies).
Mitochondrial Dna Quantification
Circulating DNA was extracted and purified using the QIAamp 
DNA Blood Mini Kit (Qiagen, Germantown, MD, USA). Isolated 
DNA from mice was amplified and quantified using real-time 
(RT)-PCR. The primers (Invitrogen, Grand Island, New York, NY, 
USA) that were used to amplify mDNA were cytochrome b (Cyt 
b) (forward 5-ACCTCAAAGCAACGAAGCCT-3′ and reverse 
5′-GGTTGGCCTCCAATTCAGGT-3′), cytochrome c (Cyt c) 
(forward 5′-GACTTGCAACCCTACACGGAT-3′ and reverse 
5′-CCGGTTAGACCACCAACTGT-3′), and NADH dehydroge-
nase subunit 6 (forward 5′-ATTCCACCCCCTCACGACTA-3′ 
and reverse 5′-TGTCGTTTTGGGTGAGAGCA-3′). The primer 
sequences have no homology with DNA found in any bacterial 
species published on BLAST. The RT-PCR results are presented 
as the inverse of cycle threshold (CT) for gene amplification as 
described (57).
rna extraction and Quantitative rT-Pcr
Total RNA was extracted from the PLNs or pancreatic tissue 
using Trizol (Life Technologies, Molecular Probes, Carlsbad, 
CA, USA) following the manufacturer’s instructions. cDNA was 
obtained using a High Capacity reverse transcription kit (Applied 
Biosystems, Foster City, CA, USA). Quantitative mRNA analysis 
by RT PCR was performed using the SYBR Green fluorescence 
system (Applied Biosystems). The following primers were 
used: β-actin: 5′-AACGAGCGGTTCCGATG-3′, reverse: 
5′-GGATTCCATACCCAACAAGGA-3′, NLRP3 forward: 5′-G 
TGGATGGGTTTGCTGGGAT-3′, reverse: 5′-CCACACTCTAC 
CTAGACGC-3′; IL-1β forward: 5′-TGACAGTGATGAGAATG 
ACCTGTTC-3′, reverse: 5′-TTGGAAGCAGCCCTTCATCT-3′; 
arginase-1 forward: 5′-GTTCCCAGATGTACCAGGATTC-3′, 
reverse: 5′-CGATGTCTTTGGCAGATATGC-3′; iNOS forward: 
5′-CGTGAGTGGAGTCATACTGGAA-3′, reverse: 5′-CGAAAC 
GCTTCACTTCCAA-3′; TGF-β forward: 5′-TGAACCAAGGAG 
ACGGAATACA-3′, reverse: 5′-GGAGTTTGTTATCTTTGCTG 
TCACA-3′; Foxp3 forward: 5′-ACAACCTGAGCCTGCACAA 
GT-3′, reverse: 5′-GCCCACCTTTTCTTGGTTTTG-3′. Specific 
mRNA expression levels were normalized relative to β-actin 
mRNA levels using the comparative 2ΔΔCt method.
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FigUre s1 | il-1r deficiency reduces the Th17/Tc17/Th1 cell population 
in the pancreatic lymph nodes (Plns) in type 1 diabetes. The percentage 
and absolute numbers of CD4+IL-17+ (a,D), CD8+IL-17+ (B,e), and CD4+IFN-γ+ 
(c,F) cells in the PLNs were determined by flow cytometry. Intracellular cytokine 
levels were detected after stimulation with PMA plus ionomycin. The gate was 
set on CD3-positive lymphocytes. The concentrations of IL-6 (g), IL-17 (h), 
IFN-γ (i), TNF-α (J), IL-4 (K), and IL-10 (l) were determined in the pancreatic 
tissue by an ELISA assay. The results are expressed as the mean ± SEM (n = 9 
in the vehicle-injected wild-type (WT) group; n = 24 in the streptozotocin 
(STZ)-administered WT group; n = 9 in the vehicle-injected IL-1R−/− group; and 
n = 24 in the STZ-administered IL-1R−/− group). *p ≤ 0.05 compared to the 
vehicle-injected WT group, #p ≤ 0.05 compared to the STZ-administered WT 
group. Significant differences between the groups were compared by one-way 
ANOVA followed by Tukey’s multiple-comparison test. The results are 
representative of a single experiment repeated three times.
FigUre s2 | nOD-like receptor family-pyrin domain containing 3 (nlrP3) 
activation by mitochondrial Dna (mDna) from diabetic mice decreases the 
mast cell and myeloid-derived suppressor cell population in the pancreatic 
lymph nodes (Plns). Relative quantification of circulating mDNA genes, NADH 
dehydrogenase subunit 6 (NADH), cytochrome b (Cyt b), and cytochrome c (Cyt c) 
measured by RT-PCR of vehicle-injected or streptozotocin (STZ)-administered 
mice (a–c). The percentage and absolute numbers of CD117+FcϵRI+ (D,g), 
CD11b+CD206+ (e,h), and CD11b+Ly6C+ (F,i) in the PLNs were determined by 
flow cytometry. The concentrations of IL-1β (J), IL-6 (K), IL-17 (l), IL-23 (M), IFN-γ 
(n), or IL-10 (O) were determined in the pancreatic tissue by an ELISA assay. The 
results are expressed as the mean ± SEM [n = 12 in the wild-type (WT) group 
administered only with STZ; n = 18 in the WT group administered with STZ plus 
mDNA; n = 12 in the NLRP3−/− group administered only with STZ; and n = 18 
NLRP3−/− group administered with STZ plus mDNA]. *p ≤ 0.05 compared to the 
vehicle-injected WT group or treated only with STZ, #p ≤ 0.05 compared to the WT 
group or treated only with STZ plus mDNA, or &p ≤ 0.05 compared to the 
NLRP3−/− group administered only STZ. Significant differences between the groups 
were compared by one-way ANOVA followed by Tukey’s multiple-comparison test. 
The results are representative of a single experiment repeated three times.
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